Company Research
DaVita Inc. (DVA)
First analyzed: 2026-09-29
Part 1
Company Overview
DaVita is a scaled, largely recurring kidney-care provider whose economics are anchored by U.S. dialysis, while international expansion and value-based integrated kidney care provide growth but add reimbursement, execution and regulatory complexity.
Business Model
Overview
- DaVita provides dialysis and related laboratory services for patients with end-stage kidney disease, primarily through outpatient dialysis centers. It also operates integrated kidney care, international dialysis, clinical research, transplant software and other ancillary businesses.
- The company serves patients directly but is primarily paid by government programs, commercial health insurers, hospitals and other healthcare organizations. Nephrologists and hospitals are important referral and operating partners, while health plans and government programs are the principal economic customers.
Segments And Revenue
- Fiscal 2025 consolidated revenue was approximately $13.643 billion.
- U.S. dialysis generated approximately $11.793 billion, or 86% of consolidated revenue. This segment is the core business and includes outpatient dialysis, inpatient dialysis-related services, administrative services and related laboratory services.
- Other ancillary services generated approximately $1.922 billion, or 14% of consolidated revenue. Within ancillary services, reported 2025 revenue was approximately $1.346 billion from international operations, $542 million from U.S. integrated kidney care and $34 million from U.S. other ancillary activities. These figures are management's segment presentation and include the company's reported classifications.
- International operations represented approximately 10% of consolidated revenue in 2025 and operated 585 outpatient dialysis centers in 14 countries as of December 31, 2025. The international network was concentrated in Brazil, Colombia, Malaysia, Poland, Chile and Germany, with additional operations in the United Kingdom, Ecuador, Saudi Arabia, Panama, Portugal, China, Japan and Singapore.
- As of June 30, 2026, DaVita reported approximately 298,500 patients and 3,266 outpatient dialysis centers, including 2,671 U.S. centers and 595 centers in 14 other countries.
Payor Mix
- For U.S. dialysis patient-service revenue in 2025, approximately 57% came from Medicare and Medicare Advantage, 7% from Medicaid and managed Medicaid, 3% from other government programs and 32% from commercial payors, including hospital dialysis services.
- Government programs covered approximately 89% of U.S. dialysis patients but generated approximately 68% of U.S. dialysis patient-service revenue. Commercial patients were approximately 11% of U.S. dialysis patients but generated approximately 26% of U.S. dialysis patient-service revenue from non-hospital commercial payors.
- Commercial reimbursement rates are generally materially higher than government rates and generate nearly all of DaVita's profits from non-hospital dialysis. This creates a significant earnings sensitivity to commercial-insurance enrollment, contract rates and the transition of patients from commercial coverage to Medicare after the applicable eligibility period.
Recurring And Cyclicality
- Revenue is recurring in the operating sense: dialysis is medically necessary, treatments are delivered multiple times per week and revenue is recognized as services are provided. Patient volume is therefore more durable than demand for elective or discretionary healthcare.
- The business is not subscription-based and revenue is not contractually fixed. It is exposed to treatment volumes, mortality, transplantation, payer mix, reimbursement policy, labor costs, supply costs, collections and regulatory changes.
- DaVita is relatively defensive against ordinary economic cycles, but earnings can be cyclical or volatile through reimbursement changes, commercial-insurance mix, labor inflation, government policy, cybersecurity events and acquisitions. The 2025 filing specifically identified commercial-payer mix as a major profit driver.
History
Origins And Turnaround
- The company was incorporated in 1994 under an earlier corporate name and became Total Renal Care Holdings. In the late 1990s, it was near bankruptcy when Kent Thiry became chairman and chief executive officer.
- In 2000, the company adopted the DaVita name and launched the values-based 'Village' operating culture. The turnaround under Thiry was a foundational milestone that stabilized the company and established its distinctive employee and patient-oriented culture.
Major Acquisitions And Pivots
- In 2005, DaVita acquired Gambro Healthcare, approximately doubling its dialysis-center footprint and materially strengthening its U.S. scale.
- In 2011, the company began international expansion, later building a presence across 14 countries.
- In 2012, DaVita acquired HealthCare Partners for an announced purchase price of approximately $4.42 billion. The transaction expanded DaVita into physician networks and coordinated medical care, and the company was renamed DaVita HealthCare Partners.
- In June 2019, DaVita sold its former DaVita Medical Group business to Optum, a UnitedHealth Group subsidiary, for an aggregate purchase price of approximately $4.34 billion before specified adjustments. The sale refocused the company on kidney care and related businesses.
- The post-2019 strategy has emphasized comprehensive kidney care, integrated kidney care arrangements, international dialysis expansion, home and hospital care, clinical research, transplant-related software and value-based partnerships rather than broad ownership of primary-care medical groups.
Leadership
- Kent Thiry led the company's turnaround beginning in the late 1990s and remained a central figure for nearly two decades.
- Javier Rodriguez, who joined DaVita in 1998 and held operating and payor-contracting roles, became chief executive officer in 2019. He remained CEO as of the 2025 Form 10-K and the company's 2026 investor materials.
- David Maughan became chief operating officer of DaVita Kidney Care in September 2024 after holding several senior roles at the company.
- Robert Lang has served as president and CEO of DaVita International since April 2017 and has overseen the international business's expansion to 14 countries.
Milestones Shaping The Current Company
- The 1990s turnaround created the operating culture and management system that underpin DaVita's scale.
- The Gambro acquisition established a much larger dialysis platform.
- The HealthCare Partners acquisition demonstrated an attempt to broaden into integrated healthcare delivery.
- The 2019 medical-group sale reversed that diversification and left DaVita primarily focused on kidney care, dialysis and adjacent services.
- The current model combines a mature U.S. dialysis base with higher-growth but smaller businesses in international dialysis and risk-based integrated kidney care.
Strengths and Moat
Competitive Advantages
- Scale and density: DaVita operated or provided administrative services to 2,657 U.S. outpatient dialysis centers serving approximately 200,500 patients at December 31, 2025. A large network can spread clinical, technology, compliance, purchasing, laboratory and administrative costs across many centers.
- Clinical and operating know-how: Dialysis is a complex, highly regulated service requiring clinical protocols, trained staff, nephrologist relationships, quality reporting and reliable supply and scheduling systems. DaVita reports a long record of strong performance under CMS dialysis quality programs.
- Referral and payor relationships: Relationships with nephrologists, hospitals and commercial payors support patient referrals, medical-director coverage, hospital contracts and reimbursement negotiations. These relationships are difficult for a small entrant to replicate quickly.
- Patient and treatment data: A large longitudinal patient base can support quality measurement, care coordination, integrated kidney care and operational benchmarking. This advantage is more valuable if DaVita can convert data and clinical scale into lower total cost for payors.
- Integrated-care platform: DaVita IKC had approximately 66,000 patients in risk-based integrated care arrangements and an additional 9,400 patients in other integrated care arrangements as of December 31, 2025. These arrangements provide a path beyond fee-for-service dialysis, although they also expose DaVita to medical-cost and execution risk.
- Regulatory and compliance infrastructure: Operating thousands of centers across many jurisdictions requires substantial compliance, billing, quality and risk-management capabilities. This creates a meaningful barrier to entry for smaller providers.
Main Competitors
- Fresenius Medical Care is the largest and most direct global competitor. It also manufactures dialysis equipment and supplies, which can provide vertical-integration and purchasing advantages that DaVita generally does not possess.
- DaVita also competes with large and medium-sized dialysis providers, independent nephrologists, physician-owned centers, private-equity-backed kidney-care companies, hospitals and emerging technology or pre-dialysis providers.
- In integrated kidney care, competition includes health plans, physician groups, value-based kidney-care companies and other organizations seeking to manage chronic kidney disease and reduce avoidable medical spending.
Where Davita Wins
- DaVita is strongest where network scale, operating consistency, clinical infrastructure and relationships with nephrologists and payors matter.
- Its large U.S. footprint supports patient access, centralized capabilities and negotiating experience, while its kidney-focused specialization may allow faster operational learning than a diversified general healthcare company.
- Its international platform and integrated-care capabilities give it additional growth options beyond mature U.S. dialysis.
Where Davita Loses Or Is Vulnerable
- Fresenius has a broader vertically integrated position through dialysis equipment and supplies, potentially creating cost and supply-chain advantages.
- DaVita's profits are disproportionately dependent on a relatively small commercial-patient population because commercial reimbursement is much higher than government reimbursement.
- The company has limited control over Medicare, Medicaid and other government reimbursement rules, which account for most U.S. dialysis revenue and patients.
- Labor availability, wage inflation, clinician recruitment and retention can pressure margins because dialysis is labor-intensive and requires specialized staff.
- Large scale does not eliminate competition for medical directors, acquisition targets, patients, hospital relationships and commercial contracts. Smaller or newer entrants may also face fewer legacy compliance or infrastructure burdens.
- International growth adds currency, reimbursement, political, regulatory and integration risks and has historically produced lower margins than U.S. dialysis.
Moat Durability
- Interpretation: DaVita has a real but not impregnable moat. The strongest elements are local network density, clinical operating experience, physician and payor relationships, regulatory infrastructure and accumulated patient data.
- The moat is durable because dialysis is recurring, regulated and operationally difficult, while the patient population requires ongoing care. However, the moat is not a classic pricing-power moat: reimbursement is heavily shaped by government policy, and commercial payors can exert significant negotiating pressure.
- Long-term durability depends on maintaining quality and physician relationships, preserving commercial reimbursement, controlling labor costs, converting scale into lower total kidney-care costs and adapting to home dialysis, transplantation, new drugs and technologies that could reduce or change dialysis demand.
- Overall assessment: strong incumbent advantages in U.S. dialysis, moderate advantages in integrated kidney care, and a more variable moat internationally.
Bottom line
- DaVita is primarily a U.S. dialysis company, supplemented by international dialysis, integrated kidney care and other kidney-related services.
- Its differentiation comes from scale, clinical and operating infrastructure, physician and payor relationships and a specialized kidney-care platform, not from proprietary equipment or unconstrained pricing power.
- The most important long-term issues are commercial-payer mix, government reimbursement, labor economics, the ability to grow profitable value-based care and whether new therapies or care modalities reduce the need for conventional dialysis.
Sources
No verified source links were returned.
Part 2
Updated 2026-09-29Current Situation & Why the Stock Is in a Rut
DaVita's stock is stuck mainly because investors interpreted the August 5, 2026 selloff as a warning that strong headline EPS is masking weak treatment-volume growth, lower revenue per treatment, reimbursement and payer-mix risk, and a full-year outlook that was reaffirmed rather than raised.
Recent Performance
Period Covered
Q4 2025 through Q2 2026
Earnings
Quarter
Q4 2025
Date
February 2, 2026
Facts
- Revenue was $3.620 billion, up from $3.295 billion in Q4 2024.
- Diluted EPS from continuing operations was $2.94; adjusted diluted EPS was $3.40.
- Operating income was $561 million, or 15.5% of revenue; adjusted operating income was $586 million, or 16.2%.
- U.S. dialysis treatments declined 0.1% sequentially, and normalized non-acquired treatment growth was negative 0.6% year over year.
- Revenue per treatment was $422.60, while patient-care cost per treatment was $279.60.
- Reported consensus data showed EPS of $3.40 versus $3.24 expected and revenue of $3.62 billion versus $3.51 billion expected.
- Management initially provided 2026 adjusted diluted EPS guidance of $13.60 to $15.00 and adjusted operating-income guidance of $2.085 billion to $2.235 billion.
Interpretation
The quarter was a headline beat, but the underlying operating picture was mixed: reimbursement and revenue-per-treatment growth were strong while treatment volumes were flat to negative and patient-care costs were rising.
Quarter
Q1 2026
Date
May 5, 2026
Facts
- Diluted EPS from continuing operations was $2.87 versus $2.00 in Q1 2025.
- Operating income was $482 million, or 14.1% of revenue, versus $439 million, or 13.1%, in Q1 2025.
- Adjusted operating income was also $482 million.
- Normalized non-acquired treatment growth was 0.1% year over year.
- Revenue per treatment was $417.59 and patient-care cost per treatment was $280.11.
- Reported consensus data showed EPS of $2.87 versus approximately $2.33 expected and revenue of approximately $3.42 billion versus roughly $3.36 billion expected.
- Management raised 2026 adjusted operating-income guidance to $2.150 billion to $2.250 billion and adjusted diluted EPS guidance to $14.10 to $15.20, while maintaining free-cash-flow guidance of $1.0 billion to $1.25 billion.
Interpretation
Q1 was a material earnings beat and guidance increase, but the core dialysis volume trend remained nearly stagnant. The earnings growth was therefore more dependent on reimbursement, cost control, share repurchases and non-core businesses than on treatment growth.
Quarter
Q2 2026
Date
August 4, 2026; stock reaction on August 5, 2026
Facts
- Revenue was $3.554 billion, up approximately 5.2% year over year.
- Diluted EPS was $4.02, versus $2.95 in Q2 2025.
- Operating income was $579 million, or 16.3% of revenue, versus $506 million, or 14.8%, in Q1 2026.
- Operating cash flow was $490 million and free cash flow was $256 million.
- Reported consensus data showed EPS of $4.02 versus $3.88 expected and revenue of $3.554 billion versus approximately $3.496 billion expected.
- U.S. dialysis treatments rose 1.09% sequentially, but normalized non-acquired treatment growth was only 0.3% year over year.
- Revenue per treatment declined to $415.87 from $417.59 in Q1, while patient-care cost per treatment declined to $277.40 from $280.11.
- Management reaffirmed, rather than raised, 2026 adjusted operating-income guidance of $2.150 billion to $2.250 billion, adjusted EPS guidance of $14.10 to $15.20, and free-cash-flow guidance of $1.0 billion to $1.25 billion.
- The stock fell approximately 17% on August 5, 2026, despite the EPS and revenue beats. Market commentary attributed the reaction to lower revenue per treatment, limited treatment growth, unchanged guidance below some Street expectations, and Berkshire Hathaway selling disclosed around the earnings date.
- DaVita also incurred an additional $500 million Term Loan B-2 tranche during the quarter and repurchased 2.2 million shares at an average price of $154.95.
Interpretation
The market reaction was not to a reported earnings miss. It was a valuation and quality-of-earnings reset: investors expected another guidance increase, while the quarter showed sequential revenue-per-treatment pressure and continued dependence on reimbursement and buybacks.
Specific Events That Put Pressure On The Stock
Date
October 29, 2025
Event
Q3 2025 earnings miss
Details
Adjusted EPS was $2.51 versus reported consensus of approximately $3.23 to $3.17, and revenue was $3.420 billion versus approximately $3.43 billion expected. Management cited softer U.S. dialysis volumes, rising patient-care costs and cybersecurity-related charges.
Importance
This was the clearest fundamental earnings shock in the recent period and established investor sensitivity to volume, labor, medical-cost and cybersecurity execution.
Date
August 5, 2026
Event
Post-Q2 2026 selloff
Details
The stock declined approximately 17% even though Q2 revenue and EPS exceeded consensus. The main concerns were that revenue per treatment declined sequentially, normalized treatment growth remained very low, and full-year guidance was reaffirmed rather than raised.
Importance
This appears to be the primary reason the stock entered its current rut.
Date
August 4 to August 14, 2026
Event
Berkshire Hathaway ownership reduction
Details
Berkshire disclosed sales of DaVita shares, including approximately 182,980 shares sold around $199.55 on July 31 and a larger second-quarter reduction reported in subsequent filings.
Importance
The sales were small relative to DaVita's overall market capitalization but carried signaling value because Berkshire is a prominent shareholder. The evidence supports a sentiment effect, not a standalone fundamental explanation.
Date
August 25, 2026
Event
Humana value-based partnership announcement
Details
DaVita announced a new partnership with Humana to expand kidney-care services.
Importance
Strategically positive, but not an immediate earnings catalyst and therefore insufficient to reverse the post-Q2 valuation reset.
Margin And Operating Trend
- Consolidated operating margin improved from 14.1% in Q1 2026 to 16.3% in Q2 2026, so there is no evidence of an immediate consolidated margin collapse.
- The more important concern is the dialysis-unit economics: Q2 revenue per treatment fell sequentially, while year-to-date patient-care cost per treatment remained above the prior-year level.
- Q2 normalized non-acquired treatment growth of 0.3% was better than Q4 2025's negative 0.6% but still weak for a business whose long-term growth case depends partly on patient and treatment expansion.
The Bear Case
Company Specific Problems
Issue
Weak underlying treatment growth
Evidence
Normalized non-acquired treatment growth was negative 0.6% in Q4 2025, 0.1% in Q1 2026 and 0.3% in Q2 2026.
Why It Matters
A low-volume-growth environment makes DaVita increasingly dependent on reimbursement increases, payer mix, cost reductions and acquisitions.
Issue
Revenue-per-treatment and payer-mix pressure
Evidence
Revenue per treatment declined from $417.59 in Q1 2026 to $415.87 in Q2. Management attributed the quarter-to-quarter change partly to payer mix and normal fluctuations, partially offset by rate increases.
Why It Matters
DaVita earns materially higher rates from commercial payers than from government programs. A shift toward lower-paying government coverage or weaker commercial rates can pressure revenue and margins.
Issue
Cost inflation and labor exposure
Evidence
Management has identified compensation, health-benefit, insurance, pharmaceutical and supply costs as recurring cost pressures. Q3 2025 was specifically affected by rising patient-care costs.
Why It Matters
If reimbursement grows more slowly than labor and medical costs, the apparent stability of operating margins may prove temporary.
Issue
Leverage and capital-allocation risk
Evidence
DaVita had approximately $23.9 billion of enterprise value against approximately $11.2 billion of equity value according to a September 2026 market-data source. The company also added a $500 million Term Loan B-2 tranche in Q2 2026 and has funded aggressive share repurchases.
Why It Matters
Buybacks support EPS but increase sensitivity to interest rates, refinancing costs and any earnings downturn. The balance sheet makes the equity more exposed to a de-rating than a debt-light healthcare services company.
Issue
Cybersecurity and execution history
Evidence
Cybersecurity incident-related costs affected 2025 results, particularly general and administrative expense and cash-collection processes.
Why It Matters
A repeat incident, billing disruption or remediation cost could undermine cash flow and investor confidence.
Issue
Non-core growth businesses are not yet fully proven
Evidence
Q2 2026 integrated kidney care operating income was $40 million after a $19 million operating loss in Q1, while international operating income declined from $30 million in Q1 to $25 million in Q2.
Why It Matters
Integrated kidney care can become a growth catalyst, but its results may be variable and shared-savings economics are less predictable than the core dialysis business.
Macro And Sector Headwinds
- Medicare and Medicaid reimbursement changes, including changes to ESRD payment rules and Medicare Advantage economics.
- Potential restrictions on charitable premium assistance or changes in commercial-plan enrollment that could reduce the percentage of patients covered by higher-paying plans.
- Healthcare-policy uncertainty associated with the One Big Beautiful Bill Act, trade policy, immigration policy, labor regulation and broader reimbursement reform.
- Persistent labor shortages, wage inflation and healthcare-benefit inflation.
- Competition from Fresenius Medical Care, independent dialysis providers, home-dialysis models, new technologies and alternative kidney-care arrangements.
- Higher interest rates or wider credit spreads, which matter because DaVita uses substantial debt financing.
- The secular dialysis market is defensive but mature; defensive characteristics do not guarantee high organic growth.
Valuation
Current Snapshot
- The supplied scanner snapshot shows a price of $175.19 and trailing P/E of 14.83.
- Using the midpoint of management's 2026 adjusted EPS guidance of $14.65, the supplied price implies approximately 12.0 times midpoint adjusted EPS.
- A September 2026 market-data source reported a trailing P/E of approximately 15.2 times and forward P/E of approximately 11.4 times. This is directionally consistent with the scanner snapshot, although the exact figures differ because of price and estimate timing.
- Historical quarterly forward-P/E data from the same vendor ranged from approximately 9.2 times to 15.5 times over the displayed period. On that basis, DVA is not expensive versus its own recent history, but it is also not at the low end of the range.
- The scanner's negative price-to-book ratio is not economically useful because DaVita's accumulated treasury-stock and capital structure can produce negative book equity; P/B should not be used as a valuation anchor here.
- Peer comparison is imperfect. One market-data source reported Fresenius Medical Care at approximately 11.1 times forward earnings versus DaVita at approximately 13.6 times, while another source reported DaVita closer to 11.4 times forward earnings. The exact peer gap is therefore unverified, but the broad conclusion is that DaVita does not appear deeply discounted relative to its closest dialysis peer.
Assessment
The stock looks inexpensive on a cash-flow and forward-earnings basis only if management can deliver the midpoint or better of its guidance. The apparent cheapness is less compelling after adjusting for leverage, mature volume growth, reimbursement concentration and the possibility that buybacks are doing much of the EPS-growth work.
Analyst And Short Interest
Item
Analyst ratings
Details
MarketBeat reported a September 24, 2026 downgrade by Weiss Ratings from Buy to Hold. On August 7, TD Cowen was reported as upgrading the stock from Hold to Buy and raising its target from $201 to $220; Truist lowered its target from $250 to $215 while retaining Hold. These are secondary-source summaries; the underlying broker research notes were not independently verified.
Item
Short interest
Details
As of the September 15, 2026 settlement date, reported short interest was approximately 4.30 million shares, equal to about 6.87% of public float in one source, with roughly 6.8 days to cover. Another vendor reported 6.74% of shares outstanding and 12.67% of float because it used a different float denominator. The share count is credible; the float percentage is definition-dependent.
Item
Interpretation
Details
Short interest is meaningful but not extreme for a large healthcare-services company. It can amplify a negative earnings reaction, but it does not by itself establish that the business is structurally impaired.
Turnaround or Value Trap?
Bull Case
- DaVita continues to beat or meet the $14.10 to $15.20 2026 adjusted EPS range and converts guidance into approximately $1.0 billion to $1.25 billion of free cash flow.
- Treatment growth improves above the recent 0% to 0.3% range as the ESRD population expands, centers mature and integrated kidney-care programs generate referrals.
- Revenue per treatment stabilizes or resumes growth, particularly if commercial payer mix improves and reimbursement increases offset government-payer pressure.
- Patient-care cost per treatment falls or grows more slowly than revenue per treatment, allowing operating margin to remain near or above the Q2 2026 level.
- Integrated kidney care produces recurring shared-savings income rather than isolated quarterly gains.
- Debt reduction begins to take priority over buybacks, lowering interest expense and reducing the equity risk premium.
- The Humana partnership and other value-based-care arrangements create a credible medium-term growth narrative.
Bear Case
- Treatment growth remains near zero while the company relies on reimbursement increases and share repurchases to produce EPS growth.
- Revenue per treatment continues to decline because of payer mix, commercial-rate pressure or lower government reimbursement.
- Patient-care costs rise faster than reimbursement, pushing operating margin back toward the 2025 level.
- Management lowers 2026 guidance or gives a weak 2027 outlook after the market has already questioned the durability of current earnings.
- Debt remains high while buybacks continue, leaving less flexibility if interest rates rise or cash flow weakens.
- Integrated kidney care produces volatile shared-savings results and fails to offset stagnation in the core dialysis business.
- Regulatory or litigation developments affect reimbursement, premium assistance, antitrust exposure or commercial-plan participation.
What Would Signal A Turn
- Normalized non-acquired treatment growth consistently above 1% year over year for at least two quarters.
- Revenue per treatment stabilizing sequentially and growing year over year without relying solely on annual rate increases.
- Patient-care cost per treatment growing below revenue per treatment, with consolidated operating margin sustained around 16% or higher.
- A guidance raise rather than a simple reaffirmation, particularly for adjusted operating income or free cash flow.
- Net debt reduction alongside continued free-cash-flow generation.
- Recurring positive integrated kidney-care operating income and measurable growth in risk-based patient arrangements.
- A reduction in commercial-payer concentration risk or evidence that commercial reimbursement negotiations are stabilizing.
Key Catalysts And Dates
Date
October 28, 2026
Event
Next earnings date estimated by a market-data source, after market close.
Status
Estimated, not company-confirmed in the sources reviewed.
Watch
Q3 treatment growth, revenue per treatment, patient-care cost per treatment, guidance status and debt/share-repurchase activity.
Date
Q3 2026 earnings release
Event
The most important near-term catalyst.
Watch
Whether management explains the Q2 revenue-per-treatment decline as temporary payer mix or as a persistent commercial-rate problem.
Date
Future 2026 and 2027 reimbursement updates
Event
Medicare, Medicare Advantage, Medicaid and commercial-payer decisions.
Status
Specific dates were not verified.
Watch
Payment-rate changes and any policy affecting commercial coverage or premium assistance.
Assessment
The stock is more likely a temporarily de-rated mature cash generator than an obvious value trap, but the recovery case requires proof that Q2's revenue-per-treatment weakness was temporary. Without renewed volume growth and stable payer economics, the low forward P/E could simply represent fair compensation for leverage, mature growth and reimbursement risk.
Evidence Assessment
Conclusion
Evidence is inconclusive but currently more consistent with a temporary valuation and expectations reset than with a proven structural breakdown.
Supporting Temporary View
- Q1 and Q2 2026 both beat reported EPS and revenue expectations.
- Q2 operating margin improved to 16.3%, and free cash flow remained substantial.
- Management maintained rather than cut full-year guidance.
- Integrated kidney care turned profitable in Q2 after a loss in Q1.
- The stock selloff was disproportionate to the reported quarter and appears to have included sentiment effects from Berkshire's selling and elevated expectations.
Supporting Structural Risk View
- Normalized non-acquired treatment growth has remained close to zero for three consecutive reported quarters.
- Revenue per treatment declined sequentially in Q2 2026.
- The business is heavily exposed to reimbursement, payer mix, labor costs and government policy.
- High leverage and aggressive buybacks increase the consequences of an earnings downturn.
- The company has not demonstrated that integrated kidney care can consistently replace weak core dialysis volume growth.
What Would Change The Assessment
Two consecutive quarters of improving treatment growth, stable or rising revenue per treatment, controlled patient-care costs and net-debt reduction would support a temporary-problem thesis. A guidance cut, recurring revenue-per-treatment declines, renewed margin compression or negative free-cash-flow surprises would make the structural-problem thesis more persuasive.
Bottom line
DaVita is a large dialysis and kidney-care services company whose earnings are supported by reimbursement, recurring treatment demand, integrated kidney care and substantial free cash flow. The stock is stuck because investors are questioning whether low-volume growth, payer-mix pressure, leverage and buyback-supported EPS growth justify even a low-teens forward P/E. The next decisive evidence will come from the estimated October 28, 2026 earnings report, especially treatment growth, revenue per treatment, patient-care cost per treatment, guidance and debt reduction.
Sources
- DaVita Q2 2026 earnings release
- DaVita Q1 2026 earnings release
- DaVita Q4 2025 earnings release
- DaVita Q2 2026 Form 10-Q
- DaVita Q2 2026 Form 8-K and earnings exhibit
- DaVita Q3 2025 earnings filing
- DaVita valuation and historical ratio data
- DaVita quarterly valuation ratios
- DaVita analyst ratings and price-target changes
- DaVita short interest data
- DaVita Q2 2026 earnings estimate comparison
- DaVita Q4 2025 earnings estimate comparison
- DaVita Q2 2026 post-earnings stock reaction
- DaVita peer valuation comparison
Research history
The current situation refreshes after a gap or at the 30-day consecutive Top-10 refresh point. Previous analyses are retained.